Fri, April 15, 2011
Thu, April 14, 2011
Wed, April 13, 2011
Tue, April 12, 2011
Mon, April 11, 2011
Sun, April 10, 2011
Sat, April 9, 2011
Fri, April 8, 2011
Thu, April 7, 2011
[ Thu, Apr 07th 2011 ] - Market Wire
Volunteering Does a Body Good
Wed, April 6, 2011
Tue, April 5, 2011
Mon, April 4, 2011
Sun, April 3, 2011
Sat, April 2, 2011
Fri, April 1, 2011
Thu, March 31, 2011
Wed, March 30, 2011
Tue, March 29, 2011
Mon, March 28, 2011
Sun, March 27, 2011
Fri, March 25, 2011
Thu, March 24, 2011

Intellipharmaceutics International Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference


//health-fitness.news-articles.net/content/2011/ .. hers-8th-annual-small-cap-equity-conference.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


NEW YORK, NY--(Marketwire - April 5, 2011) - [ Taglich Brothers, Inc. ] is pleased to announce that Dr. Isa Odidi, CEO & Founder and Shameze Rampertab, VP Finance & CFO of [ Intellipharmaceutics International Inc ]. (NASDAQ: [ IPCI ]) (TSX: [ I ]) will be presenting at our 8th Annual Small Cap Equity Conference May 3rd, 2011. The Conference will take place at the New York Athletic Club, New York City. To request additional information or to [ register ], contact [ Taglich Brothers ] at 212-779-2971 or visit [ www.taglich.com ].

About Taglich Brothers

[ Taglich Brothers, Inc ]. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.

About Intellipharmaceutics International Inc.

[ Intellipharmaceutics International Inc. ] (NASDAQ: [ IPCI ]) (TSX: [ I ]) is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix™ technology is a unique and validated multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology, Intellipharmaceutics has a pipeline of products in various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, pain and infection. To date, Intellipharmaceutics has disclosed four products that are awaiting FDA approval.


Publication Contributing Sources